Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to
estrogen receptor, by changing the conformation of ERĪ±, blocking intracellular signal
transmission, thereby inhibiting the growth of tumor cells.